BSXBoston Scientific

$42.75-56% 1Y

Is the business good?

Good

A genuinely good business: 7 of 9 health tests passed, earnings fully cash-backed (1.1×), and margins widening.

3 good, 1 neutral
Fundamental health (F-score)7 / 9SEC EDGAR · Dec 31, 2025

High fundamental quality. Nine pass/fail tests of year-over-year health from the filings.

Profits arrive as cash1.15×derived · Jun 30, 2026

Operating profit is fully backed by cash. Conversion is worsening vs a year ago.

Margin direction, 3 years+6.2 pts

Positive operating leverage, operating profit is growing faster than sales, so margins widen as the business scales.

Where ROE comes from7% ROA

Margin-driven, fat margins on slower asset turns. ROE 13% = margin × turnover × leverage.

Unless marked, from derived.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

FCF conversionmiddle of the market
Leverage (Debt/EBITDA)middle of the market

Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.

How good a business is BSX?

Boston Scientific earns 8.8% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.

8.8%

Return on invested capital · cost of capital 9.0% · 0.20 points below what the capital costs: growth destroys value

Operating margin
20%

Operating margin · Medical Devices median 2.1% · 12 months to Q2 2026

Cash conversion
1.15×

Cash conversion · 1.64× a year ago · operating cash flow covers the operating profit after tax

Share count, year on year
−1.3%

Share count, year on year · bought back, each share owns more of the company

Operating margin by fiscal year
YearOperating margin
FY2020−0.81%
FY202110%
FY202213%
FY202316%
FY202416%
FY202518%
Details›
Gross margin12 months to Q2 2026
70%
Operating margin12 months to Q2 2026
20%
Net margin12 months to Q2 2026
17%
Free cash flow margin
17%
R&D as % of revenue
10%
Revenue, trailing twelve months
$21.0B
Free cash flow, trailing twelve months
$3.63B
Net income, trailing twelve months
$3.67B
Return on invested capitaloperating profit after tax ÷ debt + equity − cash
8.8%

Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.